Clinical Study | Open Access
Sustain Released Bupropion in the Treatment of Tricotillomania: Outpatient Follow Up Survey
Objectives. Tricotillomania (TTM) is more common than expected. SSRI's are the treatment of choice in TTM. However, response rates are lower with SSRI's. The aim of our study is to explore other pharmacological interventions. Materials and Methods. Nine female TTM patients with SSRI treatment failure were included. Sample was treated with bupropion SR up to 450 mg/day. Results. Six out of nine patients responded well to bupropion SR. Massachusetts General Hospital Hair Pulling Scale (MGH) demonstrated a significant improvement at the twelve week point (f: 32.3, power: 1, lambda: 97.1, ) and the response rates remained stable at sixteen-month follow up visit. Conclusions. Bupropion SR could be an alternative pharmacological treatment for TTM. Larger samples with double blind placebo controlled design are needed to confirm our preliminary report.
- G. A. Christenson, T. B. MacKenzie, and J. E. Mitchell, “Adult men and women with trichotillomania: a comparison of male and female characteristics,” Psychosomatics, vol. 35, no. 2, pp. 142–149, 1994.
- ICD-10 Classification of Mental & Behavioral Disorders, World Health Organization, 1992.
- American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC, USA, 4th edition, 1994.
- D. A. Regier, W. E. Narrow, and D. S. Rae, “The epidemiology of anxiety disorders: the epidemiologic catchment area (ECA) experience,” Journal of Psychiatric Research, vol. 24, pp. 3–14, 1990.
- E. Hollander, S. Kim, S. Khanna et al., “Obsessive-compulsive disorder and obsessive-compulsive spectrum disorders: diagnostic and dimensional issues,” CNS Spectrums, vol. 12, pp. 5–13, 2007.
- E. Hollander and C. M. Wong, “Obsessive-compulsive spectrum disorders,” Journal of Clinical Psychiatry, vol. 56, pp. 3–6, 1995.
- S. Lochner, S. Seedat, P. du Toit et al., “Obsessive compulsive disorder and tricotillomania: a phenomenological comparison,” BMC Psychiatry, vol. 5, article 2, 2005.
- S. E. Stewart, M. A. Jenike, and N. J. Keuthen, “Severe obsessive-compulsive disorder with and without comorbid hair pulling: comparisons and clinical implications,” Journal of Clinical Psychiatry, vol. 66, no. 7, pp. 864–869, 2005.
- S. R. Chamberlain, N. A. Fineberg, A. D. Blackwell, L. Clark, T. W. Robbins, and B. J. Sahakian, “A neuropsychological comparison of obsessive-compulsive disorder and trichotillomania,” Neuropsychologia, vol. 45, no. 4, pp. 654–662, 2007.
- A. van Minnen, K. A. L. Hoogduin, G. P. J. Keijsers, I. Hellenbrand, and G.-J. Hendriks, “Treatment of trichotillomania with behavioral therapy or fluoxetine: a randomized, waiting-list controlled study,” Archives of General Psychiatry, vol. 60, no. 5, pp. 517–522, 2003.
- N. J. Keuthen, R. L. O'Sullivan, P. Goodchild, D. Rodriguez, M. A. Jenike, and L. Baer, “Retrospective review of treatment outcome for 63 patients with trichotillomania,” American Journal of Psychiatry, vol. 155, no. 4, pp. 560–561, 1998.
- K. M. Gadde, R. H. Wagner, II, K. M. Connor, and M. S. Foust, “Escitalopram treatment of trichotillomania,” International Clinical Psychopharmacology, vol. 22, no. 1, pp. 39–42, 2007.
- G. A. Christenson, T. B. Mackenzie, J. E. Mithchell et al., “A placebo controlled double-blind crossover study of fluoxetine in Tricotillomania,” American Journal of Psychiatry, vol. 148, pp. 1566–1571, 1991.
- M. H. Bloch, A. Landeros-Weisenberger, P. Dombrowski et al., “Systematic review: pharmacological and behavioral treatment for trichotillomania,” Biological Psychiatry, vol. 62, no. 8, pp. 839–846, 2007.
- W. R. Yates, J. Mitchell, A. J. Rush et al., “Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR∗D,” General Hospital Psychiatry, vol. 26, no. 6, pp. 421–429, 2004.
- B. W. Palmer, P. V. Jeste, and J. I. Scheikh, “Anxiety disorders in the elderly: DSM-IV and other barriers to diagnosis and treatment,” Journal of Affective Disorders, vol. 46, pp. 183–190, 1997.
- J. A. Himle, P. S. Bordnick, and B. A. Thyer, “A comparison of trichotillomania and obsessive-compulsive disorder,” Journal of Psychopathology and Behavioral Assessment, vol. 17, no. 3, pp. 251–260, 1995.
- S. M. J. Hemmings, C. J. Kinnear, C. Lochner et al., “Genetic correlates in trichotillomania—a case-control association study in the South African Caucasian population,” Israel Journal of Psychiatry and Related Sciences, vol. 43, no. 2, pp. 93–101, 2006.
- M. Rubinstein, T. J. Phillips, J. R. Bunzow et al., “Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine,” Cell, vol. 90, no. 6, pp. 991–1001, 1997.
- J.-H. Lee, H.-T. Kim, and D.-S. Hyun, “Possible association between serotonin transporter promoter region polymorphism and impulsivity in Koreans,” Psychiatry Research, vol. 118, no. 1, pp. 19–24, 2003.
- D. D. Dougherty, R. Loh, M. A. Jenike, and N. J. Keuthen, “Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?,” Journal of Clinical Psychiatry, vol. 67, no. 7, pp. 1086–1092, 2006.
- A. De Sousa, “An open-label pilot study of naltrexone in childhood-onset trichotillomania,” Journal of Child and Adolescent Psychopharmacology, vol. 18, no. 1, pp. 30–33, 2008.
- C. Lochner, S. Seedat, D. J. H. Niehaus, and D. J. Stein, “Topiramate in the treatment of trichotillomania: an open-label pilot study,” International Clinical Psychopharmacology, vol. 21, no. 5, pp. 255–259, 2006.
- M. Hamilton, “The assessment of anxiety states by rating,” The British Journal of Medical Psychology, vol. 32, no. 1, pp. 50–55, 1959.
- M. Hamilton, “A rating scale for depression,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 23, pp. 56–62, 1960.
- S. Spiga, A. Lintas, and M. Diana, “Addiction and cognitive functions,” Annals of the New York Academy of Sciences, vol. 1139, pp. 299–306, 2008.
- S. W. Clay, J. Allen, and T. Parran, “A review of addiction,” Postgraduate Medicine, vol. 120, no. 2, pp. E01–E07, 2008.
- M. A. Sullivan and L. S. Covey, “Nicotine dependence: the role for antidepressants and anxiolitics,” Current Opinion in Investigational Drugs, vol. 3, pp. 262–271, 2002.
- S. Tardieu, Y. Poirier, J. Micallef, and O. Blin, “Amphetamine-like stimulant cessation in an abusing patient treated with bupropion,” Acta Psychiatrica Scandinavica, vol. 109, no. 1, pp. 75–77, 2004.
- T. Chan-Ob, N. Kuntawongse, and V. Boonyanaruthee, “Bupropion for amphetamine withdrawal syndrome,” Journal of the Medical Association of Thailand, vol. 84, no. 12, pp. 1763–1765, 2001.
- F. R. Levin, S. M. Evans, D. M. McDowell, D. J. Brooks, and E. Nunes, “Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder,” Journal of Addictive Diseases, vol. 21, no. 2, pp. 1–16, 2002.
- N. Zwar and R. Richmond, “Bupropion sustained release. A therapeutic review of Zyban,” Australian Family Physician, vol. 31, no. 5, pp. 443–447, 2002.
- D. W. Black, S. Arndt, W. H. Coryell et al., “Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study,” Journal of Clinical Psychopharmacology, vol. 27, no. 2, pp. 143–150, 2007.
- P. N. Dannon, K. Lowengrub, E. Musin, Y. Gonopolski, and M. Kotler, “Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study,” Journal of Clinical Psychopharmacology, vol. 25, no. 6, pp. 593–596, 2005.
Copyright © 2010 Pinhas N. Dannon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.